Castro, Brenda F. M. http://orcid.org/0000-0002-3604-8757
Steel, Jason C. http://orcid.org/0000-0003-3608-7542
Layton, Christopher J. http://orcid.org/0000-0001-6933-9991
Funding for this research was provided by:
The University of Queensland
Article History
Accepted: 20 September 2023
First Online: 25 October 2023
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions.
: Christopher J. Layton owns shares in Ocugene, a gene therapy company. Jason C. Steel has been a consultant for Ocugene and owns intellectual property in breast cancer gene therapy. Brenda F. M. Castro has no relevant financial or non-financial interests to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conception and design of the work: BFMC, JCS, CJL. Writing – original draft: BFMC, CJL. Writing – review and editing: BFMC, JCS, CJL. Supervision, funding acquisition and resources: CJL. All authors read and approved the final version of the manuscript.